Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal

BSE3137.0548.05 (+1.56 %)

PREV CLOSE ( ) 3089.00

OPEN PRICE ( ) 3072.35

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 13997

TODAY'S LOW / HIGH ( )3064.00 3210.20

52 WK LOW / HIGH ( )2295.1 3542.6

NSE3135.5046.1 (+1.49 %)

PREV CLOSE( ) 3089.40

OPEN PRICE ( ) 3089.90

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 3135.50 (56)

VOLUME 528369

TODAY'S LOW / HIGH( ) 3063.00 3208.90

52 WK LOW / HIGH ( )2293.55 3540

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-02 1995

Management Info

Arvind Lal - Chairman - Managing Director

Registered Office

Address Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone 011-30258600

Email lalpathlabs@lalpathlabs.com

Website www.lalpathlabs.com

Registrars Details

MUFG Intime India Pvt Ltd.

Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi

Listing : BSE, NSE

NEWS

01Nov Dr. Lal PathLabs informs about receipt
Pursuant to the provisions of Regulation 30 read with Schedule III of th..

01Nov Dr. Lal PathLabs informs about press r
Dr. Lal PathLabs has informed that it attached the copy of newspaper adv..

24Sep Dr. Lal Pathlabs gets nod to acquire p
Dr. Lal Pathlabs has received approval from its Board to acquire immovab..

24Sep Dr. Lal PathLabs informs about acquis
Dr. Lal PathLabs has informed that the Board of Directors, on September..

20Aug Dr. Lal Pathlabs pioneers AI integrati
Dr. Lal Pathlabs has become the first laboratory in the country to adopt..

Financials

Rs. in Millions

	QTR Sep 25	ANNUAL 25
Net Profit	1457	4973
Gross Profit	1948	6213
Operating Profit	2379	7770
Net Sales	6996	23516

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr Agarwals Eye Hsp (BSE) 5235.70 (1.21%)	M.Cap ( in Cr)2530.32
Thyrocare Tech. (BSE) 1396.60 (3.54%)	M.Cap ( in Cr)7409.51
Indraprastha Medical (BSE) 603.90 (2.22%)	M.Cap ( in Cr)5536.13
Yatharth Hospital (BSE) 796.75 (1.14%)	M.Cap ( in Cr)7677.03
Kaya (BSE) 446.15 (1.99%)	M.Cap ( in Cr)677.60

Shareholding Pattern

	PROMOTERS	53.21%
	MUTUAL FUNDS/UTI	15.9%
	NON-INSTITUTION	6.58%
	FI/BANKS/INSURANCE	2.11%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
NJ ELSS Tax Saver S...	3.99
Bajaj Finserv Healt...	2.82
PGIM India Healthca...	2.36
Nippon India Pharma...	2.31
Quantum Ethical Fun...	2.15
DSP Nifty Smallcap2...	2.09
NJ Flexi Cap Fund-Reg(G)	2.03

Risk Disclosures on Derivatives

Smart Quotes

DR. LAL PATHLABS LTD.